[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
January 24/31, 2001

Breast Cancer Prevention Study Aims to Overcome Drug Bias

Author Affiliations
 

Not Available

Not Available

JAMA. 2001;285(4):399-400. doi:10.1001/jama.285.4.399-JMN0124-3-1

Washington—Organizers of a large breast cancer prevention study are calling on primary care physicians to be more active in finding candidates for the trial, called STAR (Study of Tamoxifen and Raloxifene), which is seeking 22 000 postmenopausal women in whom to compare the drugs tamoxifen (Nolvadex, Astra-Zeneca) and raloxifene (Evista, Eli Lilly & Co).

First Page Preview View Large
First page PDF preview
First page PDF preview
×